Astria Therapeutics, Inc. (NASDAQ:ATXS) Given Consensus Recommendation of “Buy” by Brokerages
Astria Therapeutics, Inc. (NASDAQ:ATXS – Get Free Report) has received an average rating of “Buy” from the eight ratings firms that are currently covering the firm, MarketBeat reports. Six analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month price target […]
Astria Therapeutics, Inc. (NASDAQ:ATXS – Get Free Report) has received an average rating of “Buy” from the eight ratings firms that are currently covering the firm, MarketBeat reports. Six analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month price target […]
